Alto Neuroscience, Inc. ANRO
26.49
(0.69)
(2.54%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 0.0×
Follow ANRO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
15.42 | 15.69 | 20.52 | 14.85 |
Net Debt/EBITDA |
7.80 | 9.32 | 9.10 | 7.78 | |
Debt/Assets |
15.26% | 10.28% | 6.64% | 7.34% | |
Debt/Equity |
0.20 | 0.13 | 0.08 | 0.09 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.70 | 0.71 | 1.03 | 0.72 | |
Capex/Depreciation |
0.00 | 0.00 | (3.02) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.37) | (0.40) | (0.84) | (0.46) | |
Cash per Share |
5.08 | 6.12 | 8.02 | 5.69 | |
Shareholders Equity per Share |
4.12 | 5.24 | 7.40 | 5.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.12 | 5.24 | 7.40 | 5.12 | |
Free Cash Flow |
(9.92) | (11.52) | (27.65) | (19.76) | |
Working Capital |
130.40 | 166.39 | 256.01 | 230.67 | |
Capital Expenditures |
0.00 | 0.00 | (0.56) | 0.00 | |
Net Current Asset Value |
104.00 | 144.17 | 236.24 | 212.50 | |
| Other line items | |||||
Quick Ratio |
15.24 | 15.58 | 20.11 | 14.64 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.40) | (0.82) | (0.46) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Average Payables |
2.16 | 1.73 | 2.38 | 2.85 | |
Average Assets |
169.31 | 181.12 | 224.09 | 205.97 | |
Average Common Equity |
138.30 | 151.30 | 191.23 | 171.33 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates